Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer

All patients with surgical stage III or IVA endometrial carcinoma per FIGO 2009 staging criteria including clear cell and serous papillary and undifferentiated carcinoma

* Surgical stage III disease includes those patients with positive adnexa, parametrial involvement, tumor invading the serosa, positive pelvic and/or para-aortic nodes, or vaginal involvement

* Surgical stage IVA patients with bladder or bowel mucosal involvement, but no spread outside the pelvis

Patients with FIGO 2009 surgical stage I or II endometrial clear cell or serous carcinoma and with positive peritoneal cytology

Surgery must have included a hysterectomy and bilateral salpingo-oophorectomy; pelvic lymph node sampling and para-aortic lymph node sampling are optional

Patients with a Gynecologic Oncology Group (GOG) performance status of 0, 1, or 2

White blood cell (WBC) \>= 3,000/mcl

Absolute neutrophil count (ANC) \>= 1,500/mcl

Platelet count \>= 100,000/mcl

Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) =\< 2.5 x upper limit of normal (ULN)

Alkaline phosphatase =\< 2.5 times ULN

Bilirubin =\< 1.5 times ULN

Creatinine =\< institutional ULN

Patients who have met the pre-entry requirements; testing values/results must meet eligibility criteria

Patients who have signed an approved informed consent and authorization permitting release of personal health information

Entry into the study is limited to no more than 8 weeks from the date of surgery

Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer, are excluded if there is any evidence of active malignancy within the last five years; patients are also excluded if their previous cancer treatment contraindicates this protocol therapy

Patients with a history of serious co-morbid illness or uncontrolled illnesses that would preclude protocol therapy

Patients with an estimated survival of less than three months

Patients with FIGO 2009 stage IVB endometrial cancer

Patients with parenchymal liver metastases

Patients who have received prior chemotherapy for endometrial cancer

Patients with a history of myocardial infarction, unstable angina, or uncontrolled arrhythmia within 3 months from enrollment

What this study is about